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ABSTRACT 
 
Objective: To review the links between ethnicity, serology and clinical expression in systemic 
lupus erythematosus (SLE), in a single cohort followed over a 36 year period. 
Patients and methods: Patients with SLE treated at UCLH between January 1978 and 
December 2013 formed the cohort. Demographic, clinical and serological data were assessed. 
Standard methods were used for laboratory testing. Student T-test and Mann-Whitney U test 
were used for continuous variables and Fisher’s exact test for categorical variables. 
Results: 624 SLE patients were studied, 571 women (91.5%, mean age at diagnosis: 29.0±6.5 
years) and 53 men (8.5%, mean age was 29.4±15.3 years). Ethnically, 369 patients were 
European, 100 Afro-caribbean, 77 East Asian, 56 South Asian and 21 mixed ethnicity. 
East Asian patients developed the disease younger than the other ethnic groups (p<0.0001). 
Afro-caribbean patients were less frequently associated with the presence of rash and 
photosensitivity, and non-european patients were more likely to have alopecia and renal 
involvement. South Asian patients were significantly associated with musculoskeletal and 
neurological involvement, serositis, sicca syndrome and haematological features. 
Afro-caribbeans had the highest prevalence of anti-Smith, anti-RNP, anti-Ro and anti-La 
antibodies. Anti-IgG anticardiolipin antibodies were significantly associated with the non-East 
Asian groups and hypocomplementemia was common on East Asians. 
Rash, alopecia, mouth ulcers, serositis, neurological, joints and renal involvement were 
significantly associated with the presence of anti-Smith and anti-RNP antibodies in the Afro-
caribbean group, and an association of joint involvement and presence of anti-Ro and anti-La 
was also observed on this group. 
Conclusion: East Asian patients developed the disease younger than the other ethnic groups. 
Cutaneous involvement was more frequent in non-afro-caribbeans, with serosistis, joint and 
neurological involvement being more frequently diagnosed on South Asians. Anti-ENA 
antibodies were frequently associated with Afro-caribbeans. 
 
  
INTRODUCTION 
 
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of complex, 
incompletely understood aetiology, with a wide spectrum of clinical and immunological 
manifestations (1, 2). The pathogenesis and expression of the disease is likely to be influenced 
by genetic, environmental or sociodemographic factors. This multiplicity of factors helps to 
explain the variability observed in the expression of the disease, between individuals, and ethnic 
groups (2). Ethnic differences may influence the clinical expression of the disease and the 
presence of autoantibody profiles (1). Several studies have demonstrated that non-white 
individuals present at a younger age, have a higher frequency of severe renal disease and 
ultimately a worse prognosis when compared with Caucasians (3-7).  
In SLE, the most distinctive laboratory feature is the presence of autoantibodies to nuclear 
antigens including double stranded DNA (dsDNA), histones, ribonucleoprotein (RNP), and the 
Sm antigen (1, 8). Autoantibodies in SLE may be diagnostic and/or markers of disease activity, 
and may be detected before the diagnosis of the disease (8-10). 
Many studies have been shown substantial ethnic disparities in the burden of SLE, with 
consequent influence on the severity and final outcome of disease (11). Earlier studies reported 
a higher proportion of renal disease (40.5%) and renal failure (15.3%) in black SLE patients, 
who were also diagnosed at younger age (34.4±14.9 years) when compared to white patients 
(18.8%, 4.5% and 41.9±21.3 years, respectively)(11). A recent study of 42 221 SLE patients 
revealed that SLE was more frequently diagnosed in white (20.17%) and black (24.13%) 
individuals than in Asian (5.18%) patients. In addition, a higher mortality risk was observed in 
black patients (HR 1.21 [95% CI 1.10-1.33]) compared to whites and conversely, the risk was 
significantly lower among Asian (hazard ratio 0.59 [95% CI 0.40-0.86]) when compared with 
white patients. A similar result also observed in patients with lupus nephritis where the mortality 
risk was lower in Asian patients compared with white patients (12).  
Other differences between ethnic groups include the demonstration of African-American SLE 
women expressing higher serum levels of specific Toll-like receptors (TLR-9) and pro-
inflammatory cytokines (IL-6 and TNF-α) when compared to European-American women (13). 
In addition, meta-analysis studies revealed that FcyRIIIA-F158 allele, a Fcy receptor subtype, 
predisposed to lupus nephritis in Asian patients (14), and also, higher rates of lupus nephritis-
associated autoantibodies have been described in this ethnic group when compared with White 
patients (15). 
In this study we have sought to take advantage of a relatively large cohort of diverse ethnicity 
SLE patients followed up very carefully over a long period (up to 36 years). We have thus been 
able to make direct comparisons in the same cohort between the four ethnic groups. 
 
 
METHODS AND PATIENTS 
 
PATIENTS: An audit of all the SLE patients followed up in the Rheumatology department at 
University College of London Hospital (UCLH) between January 1978 and December 2013 was 
performed. Demographic, clinical and serological data were collected and reviewed. 
The study population included a total of 624 patients (571 females and 53 males) attending 
UCLH, who fulfilled the revised criteria of the American College of Rheumatology for SLE (16). 
Demographic information collected included gender, ethnicity and age at diagnosis. Information 
on ethnicity was self-designated and patients were divided according to geographical origin: 
European (which include all white patients of European ancestry), Afro-caribbean (which include 
all black patients of African descent, and also patients from the Bahamas, Belize, Bermuda, 
Anguilla, Antigua and Barbuda, British Virgin Islands, Dominica, Montserrat, Saint Kitts and 
Nevil, Barbados, Grenada, Saint Lucia, Saint Vincent and the Grenadines, Cayman Islands, 
Guyana, Jamaica, Trinidad and Tobago, Turks and Caicos Islands), South Asian (which include 
patients from the South Asia, composed by the current territories of Afghanistan, Bangladesh, 
Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; the British Indian Ocean Territory, 
Mauritius and the Tibet Autonomous Region were included as well) and East Asian (which 
include patients from the territories of China, Japan, North Korea, South Korea, Mongolia, 
Taiwan and Vietnam). Patients of mixed origin were excluded from the analysis as well as 
patients from the countries of Somalia and Eritrean (based on the difficulty of categorisation and 
the small number of patients). 
METHODS: The routine laboratory serology results were analysed by standard methods. From 
1978 to 1988, a radioimmunoassay (Amersham, UK) was used in the serial measurement of 
anti-DNA antibody levels. From April 1988, we have used an ELISA (Cambridge Life Sciences). 
In each case, we regarded twice the upper limit of normal (25 and 100U, respectively) 
recommended by the manufacturers as a raised level. Three raised levels were required or a 
positive Crithidia lucida test before a patient was recorded as DNA antibody positive. Patients 
had approximately 5-yearly re-assessments of antibodies to Ro/SSA, La/SSB, Sm and RNP 
[originally by counter-immunoelectrophoresis, and since 1988 by ELISA (Shield Diagnostics, 
Dundee)] as well as repeated Coombs’ tests, rheumatoid factor assessments and lupus anti-
coagulants. The assays used have been described in detail elsewhere (17, 18). For the long-
term follow-up serological part of this study, we have used the routine DNA antibody and serum 
C3 results (measured by laser nephelometer using UK approved standards, normal range 0.75-
1.75 ug/ml; three reduced levels were required before the patient was regarded as being ‘low’ 
C3). The C3 levels were expressed as a proportion of the lower limit of normal and (because of 
the change in assay) the DNA binding antibodies as a fraction of the upper limit of normal (i.e. 
irrespective of the assay). Solid-phase assays for anti-Ro/SSA (17, 19), anti-La/SSB (17, 20) 
and anti-U1 RNP and anti-Sm (17) were performed using affinity-purified antigens prepared 
from calf thymus tissue extract. Solid-phase assays for anti-ribosomal ‘P’ and Western blotting 
were performed as previously described (17, 21). RF was detected using the latex fixation 
method (Becton Dickinson, Sparks, Maryland, USA). Titres of ≥1:80 were considered positive. 
The presence of antinuclear antibodies (ANA) was tested using dilutions of serum on a human 
epithelial cell line (HEp-2). Fluorescence at a titre ≥1:80 was considered positive. Ig and IgM 
anti-cardiolipin tests were done by commercial ELISE and lupus anti-coagulant by the dilute 
Russell’s viper venom time and the anti-thyroid antibody tests by immunofluorescence. 
The autoantibody profiles were obtained at or shortly after diagnosis. As previously published 
(????), 17% of patients with positive ANAs in our group become negative over a decade. In 
addition, high dsDNA antibody levels likewise tend to normalise over time, whereas, ENA 
antibody profiles presented some fluctuation but overall most of these patients tended to keep 
the same patterns over the time (????). 
The disease manifestations of the study group were collected at diagnosis, with the new clinical 
features been cumulatively added over time. 
 
STATISTICAL ANALYSIS: Descriptive results are presented as frequencies (%), mean or 
standard deviation. Comparisons between continuous variables were made using student T test 
and Mann-Whitney U test. Fisher’s exact test was used for categorical variables when it was 
appropriate. Values of p<0.05 (two tailed) were considered significant. 
 
 
RESULTS 
A total of 624 SLE patients were studied, 571 patients were women (91.5%), with a mean age 
at diagnosis of 29.0±12.3 years (7 to 77 years) and 53 patients males (8.5%), with a mean age 
at diagnosis of 29.4±15.3 years (1 to 63 years). No significant differences were found between 
gender and the age at diagnosis (T-value=0.256, p=0.798). 
369 SLE patients were European (59.1%), 100 patients were Afro-caribbean (16.0%), 77 
patients were East Asian (12.3%) and 56 patients were South Asian (9.0%). Twenty patients 
were of mixed ethnicity and in 1 patient the information was missing. 
Females were more frequently affected in all ethnic groups, with no significant difference found 
between genders in the different ethnic groups (p=0.324-1.00) (Table 1).   
East Asian patients developed the disease younger than the European, Afro-caribbean and 
South Asian patients (T-value=4.154-5.597, p<0.0001) (Table 1). No statistically significant 
differences were observed in the age at diagnosis between genders. 
The clinical profile analysis of the ethnic groups is described on Table 2, and shows a significant 
association of musculoskeletal involvement in the South Asian group, presented in all patients, 
when compared to the other ethnic groups (100% vs 81.0% to 92.9%, respectively, p=0.0002-
0.039); been a less frequent clinical feature in Afro-caribbean patients (81.0% vs 92.2% to 
100%, respectively, p=0.0002-0.049). 
The European group was significantly associated with the presence of rash (70.9%, compare to 
46.9% in Afro-caribbean and 63.6% in East Asian, respectively, p<0.0001) and photosensitivity 
(49.2% vs 8.2% in Afro-caribbean, p<0.0001). In contrast, these patients were less likely to 
have alopecia than the other ethnic groups (16.0% vs 28.6% to 38.0%, respectively, p=0.0001-
0.014). Afro-caribbean patients complained less frequently of photosensitivity when compared 
with the other ethnic groups (8.2% vs 37.7% to 49.2%, respectively, p<0.0001). 
Notably, renal involvement was less frequently diagnosed in European patients than in Afro-
caribbean and East Asian patients (24.1% vs 36.4% and 49.4%, respectively, p=0.0001-0.021). 
Interestingly, South Asian patients developed more frequently ocular lesions (sicca syndrome) 
when compared to Afro-caribbean and East Asian patients (16.1% vs 3.1% and 3.9%, 
respectively, p=0.009-0.029); as well as, serositis (55.4% compared to 31.2% in East Asian, 
35.0% in Afro-caribbean and 37.8% in European patients, respectively, p=0.007-0.019), 
neurological symptoms  (39.3% compared to 15.8% in East Asian, 19.6% in European and 
20.0% in Afro-caribbean patients, respectively, p=0.002-0.014) and leukopenia (50.0% 
compared to 25.3% in Afro-caribbean, 27.6% in East Asian and 27.9% in European patients, 
respectively, p=0.002-0.011). 
The Afro-caribbean group presented less frequently thrombocytopenia when compared to 
European and South Asian patients (7.1% vs 15.3% and 21.4%, respectively, p=0.012-0.032). 
No other statistical significant differences where observed in the other clinical categories. 
Analysing the serological data, the frequency of ANA and anti-dsDNA antibodies was similar in 
all groups (table 3), with a mean variation ranging between 89.0 to 96.4% and 61.6 to 67.6%, 
respectively. 
Afro-caribbean patients had the greatest prevalence (1/3 of the patients) of anti-Smith 
antibodies, when compared to the other ethnic groups (37.5% vs 9.5% to 17.6%, respectively, 
p=0.0001-0.006). 
In addition, in comparison to European patients the Afro-caribbean group had a higher 
prevalence of anti-Ro (53.1% vs 32.2%, respectively, p=0.0002) and anti-La (20.8% vs 11.7%, 
respectively, p=0.028) antibodies. 
The Afro-caribbean group as also the higher prevalence of anti-RNP antibodies (53.1% 
compared to 20.3% in European, 28.6% in South Asian and 34.7% in East Asian patients, 
respectively, p=0.0001-0.012), being a less frequent expression in European patients (20.3% 
compared to 34.7% in East Asian and 53.1% in Afro-caribbean patients, respectively, p=0.0001-
0.013). 
In the European group, hypocomplementemia (low C3) is a less common feature, occurring in 
38.9% of the patients (compared to 65.8% of the East Asian patients and 50.5% of the Afro-
caribbean patients, respectively, p=0.0001-0.039). 
The anti-IgG anticardiolipin is detected less frequently in the East Asian patients when 
compared to European and South Asian patients (7.9% vs 21.8% and 25.0%, respectively, 
p=0.004-0.012). 
The analysis of clinical and serological links between the ethnic groups (table 4) revealed a 
significantly association in the development of several clinical features and presence of anti-Sm 
and anti-RNP in Afro-caribbean patients when compared to the other ethnic groups, namely, 
development of rash (34.1% vs 9.2% to 14.9% of anti-Smith antibodies positivity, respectively, 
p=0.001-0.049; and 56.8% vs 19.2% to 31.9% of anti-RNP antibodies positivity, respectively, 
p=0.0001-0.027), alopecia (anti-Smith positivity in 45.9% compared to 11.9% of European 
patients, respectively, p=0.0003; and anti-RNP positivity in 64.9% of Afro-caribbean and 50% of 
East Asian compared to 20.3% of European, respectively, p=0.0001-0.019), mouth ulcers 
(36.8% of Afro-caribbean and 26.3% of South Asian vs 0% of East Asian and  5.2% of 
European patients with anti-Sm positivity, respectively, p=0.0005-0.047; and 57.9% compared 
to 15.5% of European group with anti-RNP, respectively, p=0.0002), musculoskeletal 
involvement (36.7% vs 9.7% to 17.6% with anti-Smith, p=0.0001-0.016; and 53.2% vs 19.6% to 
34.8% with anti-RNP positivity, respectively, p=0.0001-0.03), serositis (45.5% compared to 
10.1% in European and 16.1% in South Asian patients with anti-Sm, p=0.0001-0.015; and with 
anti-RNP positivity 57.6% compared to 21.6 and 32.3% on the same groups, respectively, 
p=0.0002-0.049), renal involvement (42.9% vs 11.2% of European patients with anti-Smith, 
p=0.0002; and 60% compared to 18% in European and 33.3% in East Asians with anti-RNP, 
p=0.0001-0.033), neurological involvement (with anti-Sm 47.4% vs 5.6% of European and 
13.6% of South Asians, p=0.0001-0.037; and 42.1% vs 15.3% of Europeans with anti-RNP 
positivity, respectively, p=0.022), leukopenia (with anti-Smith positivity 33.3% vs 10.9% of 
European patients, respectively, p=0.011) and lymphopenia (39.4% vs 10.2% to 18.2% of the 
other groups with anti-Sm positivity, p=0.0001-0.021; and 60.6% vs 21.4% to 37.0% with anti-
RNP, respectively, p=0.0001-0.022). In addition, Afro-caribbean patients have high serological 
expression of anti-Ro and anti-La in association with rash (54.4 and 27.3% compared to 33.0% 
and 12.6% in European patients, respectively, p=0.01 and 0.019), alopecia (56.8% vs 33.9% in 
Europeans with anti-Ro positivity, p=0.035), musculoskeletal involvement (49.4 and 22.8% vs 
31.9 and 11.1% in European patients, respectively, p=0.004 and 0.009), neurological 
involvement (63.2% with anti-Ro positivity compared to 18.2% of East Asian and 33.3% of 
European patients, p=0.026) and lymphopenia (57.6% compared to 34.1% of Europeans with 
anti-Ro positivity, respectively, p=0.001). 
In East Asian patients hypocomplementemia was a common presentation been associated with 
cutaneous symptoms (rash, photosensitivity or alopecia) (64.6%, 67.9% and 77.2% compared 
to 36.9%, 35.8% and 40.7% in Europeans, respectively, p=0.0004, 0.002 and 0.005), mouth 
ulcers (70.6% vs 34% of European patients, p=0.007), musculoskeletal involvement (65.7% 
compared to 38.1% in European and 49.4% in Afro-caribbeans, respectively, p=0.0001-0.049), 
serositis (70.8% vs 38.8% of Europeans, p=0.006), neurological involvement (91.7% compared 
to 47.2% of Europeans and 50% of Afro-caribbeans, respectively, p=0.004-0.023) and 
haematological features (leukopenia, lymphopenia and thrombocytopenia) (85.7%, 70.7% and 
80% compared to 45.4%, 41.5% and 43.6% of European patients, respectively, p<0.0001 to 
0.044). 
Interestingly, East Asian patients less frequently express anti-IgG anticardiolipin antibodies 
when compared to European or South Asian patients, observed in patients with rash (8.3% vs 
22.8 and 26.3%, respectively, p=0.02-0.038), photosensitivity (3.6% vs 21.7% of Europeans, 
p=0.02), musculoskeletal involvement (7.1% vs 22% and 25%, respectively, p=0.003-0.011), 
serositis (4.2% compared to 25.9% of Europeans, p=0.017), renal involvement (5.3% vs 20.9% 
and 25%, respectively, p=0.034-0.047) and lymphopenia (5.3% vs 22.1% and 20.5%, 
respectively, p=0.003-0.029). 
 
 
DISCUSSION 
We have studied a relatively large number of SLE patients followed carefully over a long period 
using broadly similar assays throughout to review ethnic diversity in this disease. Although as 
discussed below, there have been other studies of this nature they were mostly multi-sites often 
using different assays to measure for example dsDNA antibodies, of much shorter duration and 
usually in involving just two or three ethnic groups. 
As expected, females were more affected by SLE (22) in each ethnic group. In our study, 
European, South Asian and Afro-Caribbean patients developed the disease later than the East 
Asian group. This result was consistent with previous reports (eg from Leicester, UK) where a 
younger age at diagnosis was observed in Asian patients (24±6 years) compared to white 
patients (31±5 years) (23).  Interestingly, and unlike our experience, previous reports have 
found that African-American females with SLE had a younger mean age at diagnosis compared 
with white females (24). 
Skin lesions in SLE are frequent (about 75% of patients) and often polymorphic (25, 26). In the 
present study skin lesions (namely rash and photosensitivity) were less frequent in the Afro-
Caribbean group features that have been observed in previous reports (7, 27-29) perhaps being 
less easily recognized in this group (30). 
A negative association with renal involvement was observed in the European patients when 
compared with the other ethnic groups, a result consistent with previous reports (6, 27, 31-33). 
In a systematic review of SLE in Asia, higher rates of renal involvement were described in Asian 
patients (21-65% at diagnosis and 40-82% at follow-up) when compared with White patients (6, 
31). Renal disease was also more common in Black SLE patients in our study as has previously 
been reported (7, 27, 32). 
All of our South Asian patients present musculoskeletal involvement (100%), a feature less 
frequent on the rest of the ethnic groups. Interestingly, Jasmin et al (33) showed that arthritis 
was a common clinical manifestation (52.3%) in a multi-ethnic Malaysian population, with 
Indians having a higher risk of arthritis compared to Malays and Chinese Malaysians. 
ANA and anti-dsDNA antibodies are the most frequent autoantibodies detected in all groups.  
Analysis of individual autoantibody specificities in the anti-ENA spectrum revealed significant 
differences among ethnic groups. Reports in Afro-Caribbean SLE patients indicate that anti-Sm, 
anti-RNP and anti-Ro were more prevalent than in those with European ancestry (28, 29, 32). 
As previously observed (27-29, 32, 34) that the Afro-caribbean SLE patients in our study had 
the greatest prevalence of anti-Sm antibodies (37.5%), which was much less common in the 
other groups (European 9.5%, East Asian 17.6%, South Asian 14.3%). 
Curiously, Li and co-workers (2014) (35) studied a Chinese SLE population of 2170 and 
observed a positivity of 44.1% for anti-phospholipid antibodies (anticardiolopin, anti-B2 
glucoprotein I antibody and LAC), a significant high number when compared to our group of 
East Asian patients where the frequency of anti-IgG and IgM anticardiolipin and LAC were of 
7.9%, 6.6% and 13% (with a total of 24.7%, 19/77, p=0.0007), respectively, and a significantly 
association between our non-East Asian patients with positivity for anti-IgG anticardiolipin 
antibodies and several clinical features (namely, rash, photosensitivity, musculoskeletal and 
renal involvement, serositis and lymphopenia). In contrast, Li and co-workers found an 
association between anti-phospholipid antibodies and haematological involvement, interstitial 
lung disease and a lower prevalence of oral ulcerations (p<0.05) (35), a result not consistent 
with our findings. 
In this study we observed that Afro-caribbeans with kidney involvement have higher positivity for 
ENA antibodies (anti-Sm and anti-RNP), as reported previously (1). In addition, in this ethnic 
group a significant association was observed between anti-Ro positivity and presence of 
cutaneous manifestations (skin rash) as previously described in literature (36, 37). 
A previous study showed that Asian ethnicity was significantly associated with a more clinically 
severe SLE, with patients being more likely to have renal disease (OR 2.9, 95% CI 1.4-5.98; 
p=0.004), a significantly higher proportion of autoantibody positivity to anti-RNP and anti-Sm, 
and an increased likelihood of hypocomplementaemia (38) which is in agreement with our 
findings. 
It is important to mention that the apparent differences observed in phenotypic expression, 
severity and even frequency of SLE between the different ethnic groups may be due to genetic 
or environmental (including cultural) factors or a combination of both (39). As the LUMINA 
(Lupus in Minorities, Nature vs nurture) study has shown, rather than ethnicity per se, a lower 
income and the socioeconomic status are independent risk factors for the disease progression 
and outcome (40). In parallel, a study has also revealed that income (but not ethnicity or 
education level) was strongly associated with renal damage in a SLE cohort of patients (41). 
Unfortunately in studies from the USA it is hard to disentangle genetic and socio-economic 
factors. However, a study from the UK (where healthcare is free at the point of access to the 
system) clearly showed that renal disease and renal failure were much more common in the 
black population (compared to the Caucasian group) strongly suggesting that genetic factors 
were highly significant in determining clinical outcome (42). 
Much discussed in literature has been the use of self-reported ethnicity in genetic and 
epidemiologic studies, which may be seen as an important bias and could lead to misleading 
information (5, 43). Of major importance, as demonstrated when examining ancestry informative 
markers, it is clear that no homogeneous racial groups exist within the human race (44). 
The key findings in this audit of ethnic differences in an SLE cohort followed for a period of up to 
36 years were that East Asian patients developed the disease younger than the other ethnic 
groups. Anti-ENA antibodies were shown to be higher in the Afro-caribbeans, and the disease 
was commonly accompanied by low C3 levels in the East Asian patients. Renal involvement 
was more frequent in non-caucasians (23) and was frequently associated with anti-ENA 
antibodies in Afro-caribbeans. 
Understanding the influence of ethnicity in disease expression, may provide a way for an 
individualised approach to risk assessment, management and monitoring of SLE. 
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Table 1 – Demographic characteristics of SLE patients per ethnic group. 
Ethnic groups Number of patients (%) Age at diagnosis  Gender (%) Age at diagnosis / gender 
European 369 (59.1) 30.6 ± 13.2 
F 334 (90.5) 30.3 ± 12.9 
M 35 (9.5) 33.3 ± 15.7 
Afro-caribbean 100 (16.0) 28.4 ± 10.9 
F 94 (94.0) 28.6 ± 11.0 
M 6 (6.0) 24.7 ± 7.2 
East Asian 77 (12.3) 21.6 ± 10.6 
F 69 (89.6) 21.9 ± 10.4 
M 8 (10.4) 18.9 ± 12.9 
South Asian 56 (9.0) 30.3 ± 10.1 
F 53 (94.6) 30.4 ± 10.0 
M 3 (5.7) 27.7 ± 14.6 
Legends: F – Female; M – Male. 
 
 
Table 2 – Clinical characteristics of SLE patients per ethnic group. 
Manifestations 
Total 
N = 624 
Ethnic Group 
European 
N = 369 
Afro-Caribbean 
N = 100 
East Asian 
N = 77 
South Asian 
N = 56 
P value 
Musculoskeletal 91,3% (569/623) 92,9% (342/368) 81,0% (81/100) 92,2% (71/77) 100% (56/56) p = 0.0002-0.049 
Cutaneous      
 
Alopecia 22,8% (142/624) 16,0% (59/369) 38,0% (38/100) 28,6% (22/77) 30,4% (17/56) 
p = 0.0001-0.014 
Photosensitivity 40,1% (247/616) 49,2% (179/364) 8,2% (8/97) 37,7% (29/77) 41,1% (23/56) 
p < 0.0001 
Malar rash (butterfly 
lesions) 
66,0% (410/621) 70,9% (261/368) 46,9% (46/98) 63,6% (49/77) 67,9% (38/56) p = 0.0001-0.012 
Oral/nasal ulcers 25,8% (160/620) 26,3% (97/369) 19,4% (19/98) 22,1% (17/77) 33,9% (19/56) 
p = 0.053-0.709 
Ocular lesions (Sicca 
syndrome) 
8,6% (53/615) 9,3% (34/364) 3,1% (3/96) 3,9% (3/76) 16,1% (9/56) 
p = 0.009-0.029 
Serositis (pleuritic 
and/or pericarditis) 
38,2% (238/623) 37,8% (139/368) 35,0% (35/100) 31,2% (24/77) 55,4% (31/56) 
p = 0.007-0.019 
Renal  31,6% (197/623) 24,1% (89/369) 36,4% (36/99) 49,4% (38/77) 42,9% (24/56) 
p = 0.0001-0.021 
Neurologic 20,9% (130/621) 19,6% (72/367) 20,0% (20/100) 15,8% (12/76) 39,3% (22/56) 
p = 0.002-0.014 
Hematologic       
Hemolytic anemia 3,7% (23/619) 3,3% (12/367) 4,1% (4/97) 5,2% (4/77) 1,8% (1/56) 
p = 0.397-1.0 
Leukopenia 29,6% (183/618) 27,9% (102/365) 25,3% (25/99) 27,6% (21/76) 50,0% (28/56) 
p = 0.002-0.011 
Lymphopenia 75,1% (464/618) 75,6% (276/365) 68,7% (68/99) 76,3% (58/76) 78,6% (44/56) 
p = 0.195-1.0 
Thrombocytopenia 14,9% (92/618) 15,3% (56/365) 7,1% (7/99) 13,2% (10/66) 21,4% (12/56) 
p = 0.012-0.032 
 
Table 3 – Serological characteristics of SLE patients per ethnic group. 
Variable 
Total 
N = 624 
Ethnic group 
European 
N = 369 
Afro-Caribbean 
N = 100 
East Asian 
N = 77 
South Asian 
N = 56 
P value 
ANA 93,8% (574/612) 93,6% (339/362) 96,0% (95/99) 89,0% (65/73) 96,4% (54/56) p = 0.127-1.0 
High-anti-dsDNA 63,4% (391/617) 62,0% (227/366) 61,6% (61/99) 67,6% (50/74) 64,3% (36/56) p = 0.429-1.0 
Anti-U1-nRNP 28,3% (174/615) 20,3% (75/369) 53,1% (51/96) 34,7% (25/72) 28,6% (16/56) p = 0.0001-0.020 
Anti-Smith 15,4% (95/616) 9,5% (35/368) 37,5% (36/96) 17,6% (13/74) 14,3% (8/56) p = 0.0001-0.006 
Anti-Ro (SSA) 36,9% (227/616) 32,2% (119/369) 53,1% (51/96) 41,1% (30/73) 39,3% (22/56) p = 0.0002 
Anti-La (SSB) 14,0% (86/616) 11,7% (43/369) 20,8% (20/96) 15,1% (11/73) 16,1% (9/56) p = 0.028 
Lupus anticoagulant 15,7% (96/611) 17,8% (64/360) 11,3% (11/97) 13,0% (10/77) 12,5% (7/56) p = 0.164-1.0 
Anti-IgG anticardiolipin 19,6% (120/612) 21,8 % (79/362) 15,6% (15/96) 7,9% (6/76) 25,0% (14/56) p = 0.004-0.012 
Anti-IgM anticardiolipin 8,0% (49/612) 9,7% (35/362) 3,1% (3/96) 6,6% (5/76) 5,4% (3/56) p = 0.038 
Coombs positive 22,1% (138/624) 19,5% (72/369) 29,0% (29/100) 27,3% (21/77) 19,6% (11/56) p = 0.054-1.0 
Anti-thyroid microsome 9,8% (61/624) 10,8% (40/369) 6,0% (6/100) 6,5% (5/77) 12,5% (7/56) p = 0.185-1.0 
Anti-thyroglobulin 4,3% (27/624) 5,7% (21/369) 2,0% (2/100) 5,2% (4/77) 0% (0/56) p < 0.0001 
RF 21,9% (129/589) 21,0% (74/352) 20,7% (19/92) 29,4% (20/68) 23,2% (13/56) p = 0.152-1.0 
Low C3 38,0% (236/621) 38,9% (143/368) 50,5% (50/99) 65,8% (50/76) 51,8% (29/56) p = 0.0001-0.039 
Legends: ANA - antinuclear antibodies; dsDNA - doublestranded DNA; RF – rheumatoid factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 – Clinical and serological characteristics of SLE patients according to 
ethnic group. 
Variables Ethnic groups 
European Afro-caribbean East Asia South Asian P value 
Rash vs anti-Sm 9.2% (24/261) 34.1% (15/44) 14.9% (7/47) 13.2% (5/38) p = 0.0001-0.049 
Rash vs anti-RNP 19.2% (50/261) 56.8% (25/44) 31.9% (15/47) 31.6% (12/38) p = 0.0001-0.027 
Rash vs anti-Ro 33.0% (86/261) 54.4% (24/44) 44.7% (21/47) 42.1% (16/38) p = 0.01 
Rash vs anti-La 12.6% (33/261) 27.3% (12/44) 12.8% (6/47) 15.8% (6/38) p = 0.019 
Rash vs low C3 36.9% (96/260) 53.3% (24/45) 64.6% (31/48) 55.3% (21/38) p = 0.0004-0.047 
Rash vs IgG 22.8% (58/254) 19.0% (8/42) 8.3% (4/48) 26.3% (10/38) p = 0.02-0.038 
Photosen. vs anti-Sm 7.8% (14/179) 12.5% (1/8) 21.1% (6/28) 8.7% (2/23) p = 0.036 
Photosen. vs anti-RNP 19.0% (34/179) 37.5% (3/8) 37.0% (10/27) 34.8% (8/23) p = 0.044 
Photosen. vs low C3 35.8% (64/179) 37.5% (3/8) 67.9% (19/28) 60.9% (14/23) p = 0.002-0.024 
Photosen. Vs IgG 21.7% (38/175) 28.6% (2/7) 3.6% (1/28) 21.7% (5/23) p =  0.02 
Alopecia vs anti-Sm 11.9% (7/59) 45.9% (17/37) 20.0% (4/20) 23.5% (4/17) p =  0.0003 
Alopecia vs anti-RNP 20.3% (12/59) 64.9% (24/37) 50.0% (10/20) 41.2% (7/17) p = 0.0001-0.019 
Alopecia vs anti-Ro 33.9% (20/59) 56.8% (21/37) 35.0% (7/20) 29.4% (5/17) p = 0.035 
Alopecia vs low C3 40.7% (24/59) 65.8% (25/38) 77.2% (17/22) 70.6% (12/17) p = 0.005-0.022 
MouthU vs anti-Sm 5.2% (5/97%) 36.8% (7/19) 0% (0/17) 26.3% (5/19) p = 0.0005-0.047 
MouthU vs anti-RNP 15.5% (15/97) 57.9% (11/19) 29.4% (5/17) 31.6% (6/19) p = 0.0002 
MouthU vs low C3 34.0% (33/97) 52.6% (10/19) 70.6% (12/17) 52.6% (10/19) p = 0.007 
Musc. vs anti-Sm 9.7% (33/341) 36.7% (29/79) 17.6% (12/68) 14.3% (8/56) p = 0.0001-0.016 
Musc. vs anti-RNP 19.6% (67/342) 53.2% (42/79) 34.8% (23/66) 28.6% (16/56) p = 0.0001-0.030 
Musc. vs anti-Ro 31.9% (109/342) 49.4% (39/79) 38.8% (26/67) 39.3% (22/56) p = 0.004 
Musc. vs anti-La 11.1% (38/342) 22.8% (18/79) 14.9% (10/67) 16.1% (9/56) p = 0.009 
Musc. vs low C3 38.1% (130/341) 49.4% (40/81) 65.7% (46/70) 51.8% (29/56) p = 0.0001-0.049 
Musc. Vs IgG 22.0% (74/336) 16.3% (13/80) 7.1% (5/70) 25.0% (14/56) p = 0.003-0.011 
Serositis vs anti-Sm 10.1% (14/139) 45.5% (15/33) 21.7% (5/23) 16.1% (5/31) p = 0.0001-0.015 
Serositis vs anti-RNP 21.6% (30/139) 57.6% (19/33) 39.1% (9/23) 32.3% (10/31) p = 0.0002-0.049 
Serositis vs low C3 38.8% (54/139) 48.6% (17/35) 70.8% (17/24) 58.1% (18/31) p = 0.006 
Serositis vs IgG 25.9% (36/139) 17.6% (6/28) 4.2% (1/24) 22.6% (7/31) p = 0.017 
Renal vs anti-Sm 11.2% (10/89) 42.9% (15/35) 24.3% (9/37) 20.8% (5/24) p = 0.0002 
Renal vs anti-RNP 18.0% (16/89) 60.0% (21/35) 33.3% (12/36) 33.3% (8/24) p = 0.0001-0.033 
Renal vs IgG 20.9% (18/86) 19.4% (7/36) 5.3% (2/38) 25.0% (6/24) p = 0.034-0.047 
Neurologic vs anti-Sm 5.6% (4/72) 47.4% (9/19) 16.7% (2/12) 13.6% (3/22) p = 0.0001-0.037 
Neurologic vs anti-RNP 15.3% (11/72) 42.1% (8/19) 45.5% (5/11) 36.4% (8/22) p = 0.022-0.032 
Neurologic vs anti-Ro 33.3% (24/48) 63.2% (12/19) 18.2% (2/11) 40.9% (9/22) p = 0.026 
Neurologic vs low C3 47.2% (34/72) 50.0% (10/20) 91.7% (11/12) 68.2% (15/22) p = 0.004-0.023 
Sicca synd. vs anti-Ro 70.6% (24/34) 0% (0/3) 100% (3/3) 44.4% (4/9) p = 0.037 
Sicca synd. vs anti-La 44.1% (15/34) 0% (0/3) 100% (3/3) 22.2% (2/9) p = 0.045 
Leukop vs anti-Sm 10.9% (11/101) 33.3% (8/24) 14.3% (3/21) 14.3% (4/28) p = 0.011 
Leukop vs anti-RNP 19.6% (20/102) 37.5% (9/24) 33.3% (7/21) 39.3% (11/28) p = 0.044 
Leukop vs low C3 45.4% (46/101) 56.0% (14/25) 85.7% (18/21) 50.0% (14/28) p = 0.003-0.015 
Lymphop vs anti-Sm 10.2% (28/275) 39.4% (26/66) 16.1% (9/56) 18.2% (8/44) p = 0.0001-0.021 
Lymphop vs anti-RNP 21.4% (59/276) 60.6% (40/66) 37.0% (20/54) 34.1% (15/44) p = 0.0001-0.022 
Lymphop vs anti-Ro 34.1% (94/276) 57.6% (38/66) 47.3% (26/55) 38.6% (17/44) p = 0.001 
Lymphop vs low C3 41.5% (114/275) 58.2% (39/67) 70.7% (41/58) 59.1% (26/44) p = 0.0001-0.034 
Lymphop vs IgG 22.1% (60/271) 15.2% (10/66) 5.3% (3/57) 20.5% (9/35) p = 0.003-0.029 
Thrombocyt. vs anti-Ro 19.6% (11/56) 50.0% (3/6) 60.0% (6/10) 50.0% (6/12) p = 0.014 
Thrombocyt. vs anti-La 3.6% (2/56) 0% (0/6) 10.0% (1/10) 25.0% (3/12) p = 0.035 
Thrombocyt. vs low C3 43.6% (24/55) 57.1% (4/7) 80.0% (8/10) 58.3% (7/12) p = 0.044 
Legend: vs – versus; Photosen. – Photosensitivity; Musc. – Musculoskeletal; Thrombocyt. – Thrombocytopenia; IgG – 
anti-IgG anticardiolipin; MouthU – Mouth ulcers; Sicca synd. – Sicca syndrome; Leukop – Leukopenia; Lymphop – 
Lymphopenia. 
 
 
